Apollo Endosurgery (NASDAQ:APEN) has received a consensus recommendation of “Hold” from the six brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $10.25.
A number of research firms have recently issued reports on APEN. Piper Jaffray began coverage on shares of Apollo Endosurgery in a report on Friday. They set an “overweight” rating and a $8.00 target price for the company. Zacks Investment Research lowered shares of Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Northland Securities reaffirmed a “buy” rating and set a $12.00 target price on shares of Apollo Endosurgery in a report on Thursday, February 8th. Roth Capital set a $10.00 target price on shares of Apollo Endosurgery and gave the stock a “buy” rating in a report on Thursday, January 4th. Finally, ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd.
In other Apollo Endosurgery news, Director Matthew S. Crawford bought 4,038 shares of the company’s stock in a transaction dated Friday, March 9th. The stock was acquired at an average price of $6.20 per share, with a total value of $25,035.60. Following the completion of the acquisition, the director now directly owns 53,715 shares of the company’s stock, valued at $333,033. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 52.80% of the stock is owned by corporate insiders.
NASDAQ:APEN opened at $5.90 on Friday. The company has a quick ratio of 1.68, a current ratio of 2.23 and a debt-to-equity ratio of 0.67. Apollo Endosurgery has a fifty-two week low of $3.55 and a fifty-two week high of $12.56.
Apollo Endosurgery (NASDAQ:APEN) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.08). The company had revenue of $16.14 million for the quarter, compared to analyst estimates of $16.64 million. Apollo Endosurgery had a negative return on equity of 64.48% and a negative net margin of 42.35%. research analysts expect that Apollo Endosurgery will post -1.44 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Apollo Endosurgery (APEN) Receives $10.25 Consensus Target Price from Analysts” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/04/16/apollo-endosurgery-apen-receives-10-25-consensus-target-price-from-analysts.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.